Navigation Links
Four Basics and Some Good Information About Beta-Blocker Treatment for High Blood Pressure
Date:10/27/2009

WILMINGTON, Del. Oct. 27 /PRNewswire/ -- If you're one of the millions of Americans taking a medicine called a beta-blocker for high blood pressure, here are some basics about this family of medicines:

  • Beta-blockers are a family of medicines also known as beta-adrenergic blocking agents. When you take beta blockers, the heart beats more slowly and with less force, reducing blood pressure. For these medicines to be effective, it is very important that they are taken regularly and without interruption, as prescribed by the doctor.
  • The prescribing information for beta-blocker medications warns against abrupt cessation of therapy with beta-blocking agents.
  • Do not stop taking your beta-blocker medicine unless your doctor advises you to. Stopping your medicine without checking with your doctor may allow blood pressure to increase and may lead to other dangers such as chest pain or heart attack.
  • When taking beta-blockers, as with most medications, it is important to continue to follow your doctor's recommendations, which may include lifestyle changes such as a healthy diet and regular physical activity.

...And Some Good Information about TOPROL-XL and its Generic Equivalent

For people whose doctors have prescribed a beta-blocker called TOPROL-XL or its generic formulation, metoprolol succinate extended-release tablets, here is information you should know:

  • Following published reports that two generic companies had recalled or suspended shipments of metoprolol succinate, AstraZeneca, the manufacturer of TOPROL-XL and its authorized generic equivalent, metoprolol succinate extended-release tablets, has increased supplies of these medicines to address a shortage
  • TOPROL-XL (metoprolol succinate) is an extended-release metoprolol for the treatment of high blood pressure
  • TOPROL-XL is a once-daily medication providing treatment of high blood pressure throughout the day

Talk to your doctor to see if TOPROL-XL is right for you.

Please see accompanying full Prescribing Information including a boxed WARNING regarding abrupt cessation of therapy at www.toprolxl.com.

Indication and important risk information you should know about TOPROL-XL(®) (metoprolol succinate) extended-release tablets.

TOPROL-XL is indicated for the treatment of high blood pressure. It may be used alone or in combination with other medications to treat high blood pressure. It's good for you to know more about your medical condition and the medicine you are taking for it. So, talk to your doctor about high blood pressure and TOPROL-XL.

Because of the possibility of serious side effects, such as chest pain or a heart attack, you should not stop taking TOPROL-XL suddenly. If your doctor decides you should stop taking TOPROL-XL, you may be instructed to slowly reduce your dose over a period of time before stopping it completely.

TOPROL-XL may not be right for everyone, especially people who have the following health conditions:

  • Extreme slowing of the heart rate
  • Sudden and severe drop in the blood pressure and blood flow through the body because the heart is not pumping normally
  • Uncontrolled heart failure
  • Slowdown of the heart's electrical signal causing a slower heart rate
  • Damage to the heart's natural pacemaker that affects the heart's rhythm unless a pacemaker device is in the body
  • Any allergies to TOPROL-XL or its ingredients

It is important to take your medications every day as directed by your doctor.

Patients who have asthma or asthma-like lung disease should, in general, not take TOPROL-XL. Your doctor may not want you to take TOPROL-XL if you are taking certain types of high blood pressure medicine; have diabetes; overactive thyroid disease; hardening of the arteries in the arms or legs, or are having major surgery.

Until you know how you will react to TOPROL-XL, avoid activities that require alertness.

In patients with high blood pressure, the most common side effects were tiredness, dizziness, depression, diarrhea, itching or rash, shortness of breath, and slow heart rate. If you experience any of these or other side effects, contact your doctor.

Please see accompanying full Prescribing Information and a boxed WARNING regarding abrupt cessation of therapy. For more information, please visit www.toprolxl.com or call the Information Center at AstraZeneca at 1-800-236-9933.

SOURCE AstraZeneca


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
3. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
4. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
5. ORTHO EVRA(R) Prescribing Information Updated
6. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
11. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... IRVING, Texas , May 5, 2017   Provista ... 1994 with more than 200,000 customers, today announced Jim ... brings a wealth of executive and business experience to Provista, ... a compounding pharmacy in California . He ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with the sound of ... from the Osteoarthritis Initiative shows that certain people who experience consistent joint popping, ... may give doctors the opportunity to treat patients before the problem becomes pronounced, potentially ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American Parkinson Disease ... than eighty-nine grant submissions all vying for nearly $1,000,000 in funding that will ... , The American Parkinson Disease Association (APDA) is focused on advancing scientific research ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... seminar to focus on current legislative activity and the latest regulatory concerns impacting ... p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at the ...
(Date:5/26/2017)... Santa Clara, Calif. (PRWEB) , ... May 26, ... ... technology, announces the integration of the CareFusion NOX-T3 portable sleep monitor with its ... that provides a consistent, browser-based interface for diagnostic device operations. With this platform, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s ... sharing bold recipes for Memorial Day entertaining that are sure to satisfy your ... Head fresh sliced meats and cheeses featured in these refreshingly balanced recipes are ...
Breaking Medicine News(10 mins):